Author flags PVLA's upcoming Phase 3 SELVA data release in Q1 2026 with positive prior trial results and recent analyst upgrade.
Unpriced research observations (excluded from Calls and Returns):
PVLA — WATCH The author flags PVLA as a watch candidate ahead of its Phase 3 SELVA data release expected in Q1 2026. Positive prior trial results and orphan/fast track designations could lead to quicker FDA approval if the data are good. Mizuho raised its price target and the company hired an FDA approval expert, which the author sees as bullish signals. resolved_entity_name_mismatch
Due for Phase 3 SELVA data release in Q1 2026. Prior trials have shown amazing results.